Clinical Trial

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Protocol Amendment History 1 change
notable Enrollment increased: 125 -> 165 participants 2026-06-09
Trial Details
NCT Number NCT05651932
Lead Sponsor K36 Therapeutics, Inc.
Collaborators: Bristol-Myers Squibb
Conditions Multiple Myeloma, Myeloma, Myeloma Multiple
Enrollment 165 participants
Start Date 2023-02-22
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-08